A U.S. supply guide · Updated 27 October 2026
American Peptide Supply and the week after a shortage
A shortage ends.
The week still needs a plan.
The FDA declared the semaglutide injection shortage resolved, but said local delays could continue. That was a national turning point, even if you were still trying to work out your next prescription.
The week still has to work
A shortage announcement can leave plenty to sort out at home. We follow what changed and what it means for the next conversation about care.
Despite the name, we don’t sell medicine. American Peptide Supply explains the U.S. shortage story.
Here, we follow injection shortages and the compounding rules around them.
How shortages made room for compounding
The list changes the rules
Some semaglutide injection products entered the shortage list in March 2022 for Wegovy and August for Ozempic. Tirzepatide injection products were first listed in December 2022; the listings did not cover every presentation.
Shortage listings relaxed some limits on compounded copies; other conditions still applied. That gave compounding more room. Compounded drugs are not FDA-approved.
The shortage exception starts to wind down
FDA first declared the tirzepatide injection shortage over on 2 October 2024. After a lawsuit prompted another look, its December decision reached the same conclusion. Semaglutide’s shortage ended on 21 February 2025.
The shortage-based exceptions began to wind down. The shortage alone could no longer justify the same compounding.
See how the dates fit togetherTwo sections of law, different jobs
503A follows a person
Section 503A of the Federal Food, Drug, and Cosmetic Act covers compounding by licensed pharmacists in state-licensed pharmacies or by licensed physicians for an identified patient with a valid prescription. A shortage headline alone can’t explain that person’s needs.
503B follows a facility
Section 503B covers FDA-registered outsourcing facilities that compound batches of sterile (germ-free) medicines. They can work without individual prescriptions, under manufacturing rules and FDA inspections. Their medicines are not FDA-approved.
What happens with your next prescription
The dates can explain why the rules changed. Your clinician and pharmacist can explain what that means for your care.
FDA distinguishes local delays from national shortages. For a personal treatment plan, the route is a licensed U.S. clinician who can prescribe, in person or through lawful telehealth.
Make room for the care conversationSources for this reading
- Declaratory Order: Resolution of Shortages of Semaglutide Injection Products
- Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products
- Compounding when Drugs are on FDA’s Drug Shortages List
- Prescription Requirement Under Section 503A — full guidance
- Information for Outsourcing Facilities
- Frequently Asked Questions about Drug Shortages
Read on 27 October 2026. All readings and their context.